Cancer waiting time audit - flowcharts

Description

Appendix 5: flow chartsSingle site brain and CNS cancer studiesResearch Study (n=0)Brain &CNS(n=1)Below threshold (n=0)Clinical audit (n=1)Above threshold (n=1)Population = cancer patients Population = cancer Population = referralsand referrals (n=0) patients (n=0) (n=1)Urgent referrals (n=1)All referrals (n=0)Key: B&A = before and after studyAudit number Sample size(WTA 1) (B&A) 45Multiple site brain and CNS cancer studiesResearch Study (n=0)Multiple sitestudiesincludingBrain & CNSBelow threshold (n=0)(n=11)Clinical audit (n=11)Above threshold (n=11)Population = cancer Population = cancer Population = referralspatients and referrals (n=1) patients (n=0) (n=10)All referrals (n=0) Urgent referrals (n=10)Audit number N Brain and CNS(WTA 212) 1Audit number N Brain and CNS(WTA 207) 2(WTA 232) 2(WTA 230) 2(WTA 206) 2(WTA 231) 3(WTA 210) 4(WTA 209) 4(WTA 229) 9(WTA 234) 13(WTA 233) 13Single site breast cancer studiesBelow threshold (n=0)Research Study (n=1)Above threshold (n=1) Population = all Audit number Sample size(WTA 19) 177referrals (n=1)Breast(n=43)Audit number (WTA 42)(WTA 36) (WTA 44)Below threshold (n=9)(WTA 41) (WTA 16)Clinical audit (n=42) (WTA 34) (WTA 8)(WTA 23) (WTA 9)Above threshold (n=33)Population = referrals(n=26)Population = cancer Population = cancerpatients and referrals (n=2) patients (n=5)All referrals (n=21) Urgent referrals (n=5)Audit number Sample size Audit number Sample size(WTA 31) ...

Informations

• Publié par: Orra
• Nombre de lectures: 93
• Langue: Français

Extrait

Appendix5:flowcharts SinglesitebrainandCNScancerstudies Brain& ( C n N = S 1) ResearchStudy(n=0) Clinicalaudit(n=1) Population=cancerpatients andreferrals(n=0) Key:B&A=beforeandafterstudy Belowthreshold(n=0) Abovethreshold(n=1) Population=cancer patients(n=0) Population=referrals =n()1 Urgentreferrals(n=1) AuditnumberSamplesize (WTA1)(B&A)45 Allreferrals(n=0)

MultiplesitebrainandCNScancerstudies Multiplesite studies including Brain&CNS (n=11) ResearchStudy(n=0) Clinicalaudit(n=11) Population=cancer patientsandreferrals(n=1) AuditnumberNBrainandCNS (WTA212)1 Belowthreshold(n=0) Abovethreshold(n=11) Population=cancer patients(n=0) Allreferrals(n=0) Population=referrals (n=10) Urgentreferrals(n=10) AuditnumberNBrainandCNS (WTA207)2 (WTA232)2 (WTA230)2 (WTA206)2 (WTA231)3 (WTA210)4 (WTA209)4 (WTA229)9 (WTA234)13 (WTA233)13

Singlesitebreastcancerstudies ResearchStudy(n=1) Breast (n=43) Clinicalaudit(n=42) Population=cancer patientsandreferrals(n=2) AuditnumberSamplesize (WTA31)496 (WTA2)(B&A) Key:B&A=beforeandafterstudy Belowthreshold(n=0) Abovethreshold(n=1) Belowthreshold(n=9) Abovethreshold(n=33) Population=cancer patients(n=5) AuditnumberSamplesize (WTA3)45 (WTA4)50 (WTA6)51 (WTA7)55 (WTA43)(B&A)5750 Population=all referrals(n=1) Auditnumber(WTA42) (WTA36)(WTA44) (WTA41)(WTA16) (WTA34)(WTA8) (WTA23)(WTA9) AuditnumberSamplesize (WTA19)177 Population=referrals (n=26) Allreferrals(n=21)Urgentreferrals(n=5) AuditnumberSamplesizeAuditnumberSamplesizeAuditnumberSamplesize (WTA5)50(WTA26)249(WTA11)83 (WTA10)80(WTA29)408(WTA14)102 (WTA12)97(WTA30)432(WTA27)324 (WTA13)99(WTA32)594(WTA28)380 (WTA15)119(WTA35)966(WTA21)(B&A)200 (WTA17)138(WTA37)1250 (WTA18)154(WTA38)1433 (WTA20)200(WTA39)1440 (WTA22)220(WTA40)1585 (WTA24)239(WTA33)(B&A)607 (WTA25)243

Multiplesitebreastcancerstudies ResearchStudy(n=0) Multiplesite studies including Breast (n=29) Belowthreshold(n=2) Clinicalaudit(n=29) Abovethreshold(n=27) Population=cancerPopulation=cancer patientsandreferrals(n=7)patients(n=4) AuditnumberNBreastAuditnumberNBreast (WTA223)104(WTA208)23 (WTA212)363(WTA227)23 (WTA220)510(WTA224)49 (WTA213)646(WTA221)(B&A) (WTA214)983 (WTA215)1024 (WTA222)3288 Key:B&A=beforeandafterstudy Unclear(n=1) AuditnumberNBreast (WTA218)261 Auditnumber (WTA211) (WTA216) Population=referrals (n=16) Allreferrals(n=2) Auditnumber Bre N ast (WTA225)146 (WTA218)(B&A)2504 Urgentreferrals(n=13) AuditnumberNBreast (WTA226)50 (WTA209)63 (WTA210)87 (WTA217)110 (WTA219)170 (WTA232)170 (WTA206)214 (WTA231)217 (WTA229)243 (WTA230)269 (WTA233)449 (WTA234)494 (WTA207)706

Singlesitechildren’scancerstudies ( C n h = il 1 d ) ren’s ResearchStudy(n=0) Clinicalaudit(n=1) Population=cancerpatients andreferrals(n=0) Belowthreshold(n=0) Abovethreshold(n=1) Population=cancer patients(n=0) Allreferrals(n=0) Population=referrals =n()1 Urgentreferrals(n=1) AuditnumberSamplesize (WTA45)15

Multiplesitechildren’scancerstudies Multiplesite studies including Children’s )8=n( ResearchStudy(n=0) Clinicalaudit(n=8) Population=cancerpatients andreferrals(n=0) Belowthreshold(n=0) Abovethreshold(n=8) Population=cancer patients(n=1) Auditnumber NChildren’s cancers (WTA224)3 Allreferrals(n=0) Population=referrals )7=n( Urgentreferrals(n=7) AuditNChildren’s numbercancers (WTA207) (WTA230) (WTA206) (WTA233) (WTA232) (WTA231) (WTA234) 1 1 1 2 2 5 11

SinglesitelowerGIcancerstudies ( G n I = l 3 o 9 w ) er ResearchStudy(n=6) Clinicalaudit(n=33) Population=cancerpatients andreferrals(n=5) AuditnumberSamplesize (WTA57)78 (WTA63)114 (WTA69)197 (WTA74)299 (WTA84)2663 Belowthreshold(n=2) Abovethreshold(n=4) Population=cancer patients(n=2) AuditnumberSamplesize (WTA58)(B&A)90 (WTA73)(B&A)273 Belowthreshold(n=13) Abovethreshold(n=20) Population=cancer patients(n=0) Auditnumber (WTA81) (WTA83) Population=referrals )2=n( Urgentreferrals(n=1)Allreferrals(n=1) AuditnumberSamplesizeAuditnumberSamplesize (WTA82)(B&A)824(WTA79)(B&A)421 Auditnumber(WTA50)(WTA62)(WTA67) (WTA78)(WTA52)(WTA71)(WTA46) (WTA47)(WTA60)(WTA72) (WTA49)(WTA59)(WTA75) Population=referrals (n=15) Allreferrals(n=3)Urgentreferrals(n=12) AuditnumberSamplesize ( A W u T di A t 4 n 8 u ) mberSamplesi 3 z 4 e ( A W u T di A t 6 n 4 u ) mberSamples 1 i 2 z 2 e (WTA53)65 (WTA51)51(WTA66)160 (WTA65)124 (WTA54)67(WTA70)237 (WTA68)183 (WTA55)68(WTA76)319 (WTA56)69(WTA77)342 (WTA61)100(WTA80)466

MultiplesitelowerGIcancerstudies ResearchStudy(n=0) Multiplesite studies includingGI Auditnumber lower (WTA211) (n=32) Belowthreshold(n=4) (WTA239) (WTA216) Clinicalaudit(n=32) (WTA237) Abovethreshold(n=28) Population=referrals Population=cancerPopulation=cancer (n=18) patientsandreferrals(n=7)patients(n=3) Unclear(n=1)Allreferrals(n=2)Urgentreferrals(n=15) AuditnumberNLowerGI AuditNLower (WTA235)56 numberGI (WTA223)57 (WTA227)16 AuditnumberNLowerGI AuditnumberNLowerGI AuditnumberNLowerGI (WTA212)144 (WTA208)24 (WTA228)77 (WTA225)24 (WTA226)50 (WTA215)873 (WTA238)28 (WT218)(B&A) (WTA219)52 (WTA214)1061 (WTA229)56 (WTA213)1334 (WTA217)58 (WTA222)1678 (WTA210)62 (WTA209)73 (WTA206)109 (WTA231)111 (WTA232)153 (WTA240)160 (WTA230)183 (WTA233)372 (WTA234)474 (WTA207)634 (WTA236)(B&A)142

SinglesiteupperGIcancerstudies u G p I per (n=23) Belowthreshold(n=1) ResearchStudy(n=2) Abovethreshold(n=1) Belowthreshold(n=9) Clinicalaudit(n=21) Abovethreshold(n=12) Population=cancerpatients andreferrals(n=2) AuditnumberSamplesize (WTA103)208 (WTA105)383 Population=cancer patients(n=1) AuditnumberSamplesize (WTA101)124 Auditnumber (WTA97) Population=cancer patients(n=1) Auditnumber (WTA85)(WTA91) (WTA86)(WTA94) (WTA88)(WTA99) (WTA92)(WTA102) (WTA98) AuditnumberSamplesize (WTA104)235 Population=referrals )9=n( Allreferrals(n=1) AuditnumberSamplesize (WTA107)1330 Urgentreferrals(n=8) AuditnumberSamplesize (WTA87)23 (WTA89)47 (WTA90)61 (WTA93)63 (WTA95)79 (WTA96)81 (WTA100)109 (WTA106)547

MultiplesiteupperGIcancerstudies s M tu u d l i ti e p s lesite includingGI ( u n p = p 3 e 1 r ) ResearchStudy(n=0) Belowthreshold(n=4) Clinicalaudit(n=31) Abovethreshold(n=27) Population=cancer patientsandreferrals(n=8) AuditnumberNUpperGI (WTA223)48 (WTA235)64 (WTA212)64 (WTA220)295 (WTA213)636 (WTA215)813 (WTA214)834 (WTA222)995 Population=cancer patients(n=3) AuditnumberNUpperGI (WTA208)7 (WTA238)10 (WTA227)13 Auditnumber (WTA239) (WTA211) (WTA216) (WTA237) Population=referrals (n=16) Allreferrals(n=2) AuditnumberNUpperGI (WTA225)45 (WTA218)(B&A) Urgentreferrals(n=14) AuditnumberNUpperGI (WTA217)13 (WTA219)20 (WTA209)32 (WTA226)46 (WTA210)48 (WTA231)52 (WTA232)70 (WTA206)77 (WTA230)143 (WTA229)154 (WTA233)204 (WTA234)252 (WTA207)449 (WTA236)(B&A)70

Singlesitegynaecologicalcancerstudies ResearchStudy(n=0) Gynae- cological (n=16) Belowthreshold(n=4) Clinicalaudit(n=16) Abovethreshold(n=12) Population=cancer patientsandreferrals(n=1) AuditnumberSamplesize (WTA118)162 Population=cancer patients(n=1) AuditnumberSamplesize (WTA114)54 Auditnumber (WTA108) (WTA109) (WTA121) (WTA123) Allreferrals(n=3) Population=referrals (n=10) AuditnumberSamplesize (WTA111)51 (WTA117)146 (WTA122)578 Urgentreferrals(n=7) AuditnumberSamplesize (WTA110)35 (WTA112)52 (WTA113)54 (WTA115)77 (WTA116)137 (WTA119)261 (WTA120)273